Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06611579 · ClinicalTrials.gov registry record · NA

Clinical Study of the inQB8 TTVR System

A NA study of Tricuspid Valve Regurgitation, sponsored by inQB8 Medical Technologies.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
6
Study locations

NCT06611579: Recruiting NA study of Tricuspid Valve Regurgitation, sponsored by inQB8 Medical Technologies.

NCT06611579 is a NA study of Tricuspid Valve Regurgitation that is actively recruiting participants, run by inQB8 Medical Technologies. The registered enrollment target is 50 participants, below the 369-participant average among 3 other Tricuspid Valve Regurgitation trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06611579, a NA study of Tricuspid Valve Regurgitation, is actively recruiting participants, sponsored by inQB8 Medical Technologies.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
6
Study locations

Study Summary

Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.

Interventions

  • DEVICE Transcatheter Tricuspid Valve Replacement

Study Locations (6)

California

  • Cedars-Sinai Medical Center - Los Angeles
  • Los Robles Hosptial and Medical Center - Thousand Oaks

Georgia

  • Piedmont Atlanta Hospital - Atlanta

New York

  • North Shore University Hospital - Manhasset

Pennsylvania

  • Penn Presbyterian Medical Center - Philadelphia

Texas

  • Baylor Heart Hospital - Plano

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-06-01
Est. Completion 2029-10-31
Phase NA
inQB8 Medical Technologies

1 total trials

What NCT06611579 shows while recruiting

NCT06611579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 369-participant average among 3 other Tricuspid Valve Regurgitation trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Tricuspid Valve Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Transcatheter Tricuspid Valve Replacement is the first listed.

NCT06611579 lists 6 locations in 5 states (California, Georgia, New York).

Frequently Asked Questions

What is clinical trial NCT06611579 about?

NCT06611579 is a clinical study titled "Clinical Study of the inQB8 TTVR System". Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.

What is the current status of trial NCT06611579?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-06-01. Estimated completion is 2029-10-31.

What conditions does trial NCT06611579 study?

This clinical trial studies the following conditions: Tricuspid Valve Regurgitation.

What interventions are being tested in trial NCT06611579?

The interventions under investigation include: Transcatheter Tricuspid Valve Replacement (DEVICE).

Who is sponsoring clinical trial NCT06611579?

This trial is sponsored by inQB8 Medical Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06611579 being conducted?

This trial has 6 study locations across California, Georgia, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tricuspid Valve Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06611579, the US trial registry maintained by the National Library of Medicine. NCT06611579 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.